KẾT QUẢ ĐIỀU TRỊ UNG THƯ PHỔI BIỂU MÔ TUYẾN GIAI ĐOẠN IIIB–IV BẰNG THUỐC ĐÍCH TK1 THẾ HỆ 1 TẠI TRUNG TÂM UNG BƯỚU THÁI BÌNH

Abstract

Describe clinical and paraclinical characteristics and review treatment results of 1st generation TKI targeted drugs in late-stage adenocarcinoma lung cancer at the Oncology Center Thai Binh Provincial General Hospital in 2019 – 2024. Method: 39 patients with stage IIIB - IV lung cancer from January 2019 to July 2024 have EGFR gene mutations in exons 19 and 21. Results: Functional response: 28/39 patients responded functionally to treatment (accounting for 71,8%), 5 patients responded completely, accounting for 12,9%, 17,9% had unchanged disease and 10,3% had progressive disease. Objective response: We recorded 2 patients with complete response, accounting for 5,2%. The rate of patients with partial response was 48,6%, with 35,9% of patients whose disease remained unchanged. 10,3% of patients showed progressive disease. The average progression-free survival time is 7,9 months, the median is 6,9 months, the longest progression-free survival time is 19,5 months, the shortest is 2,8 months. The mean overall survival time was 18,0 ± 0.4 months, median 16,3 months. Conclusion: The most common age group is the age group 71-80 (38,5%), the male/female ratio is 1,44/1, 46,2% of patients smoke, patients are hospitalized for prolonged cough, chest pain, difficulty breathing, palpitations. cervical lymph nodes were seen (76,9%; 43,6%; 20.1%; 23,1%). Tumor location is common in the upper lobe of the right lung and in the periphery (27,6%; 43,1%), average tumor size is 4,29 ± 2 cm. Exon 19 mutations account for 64,1%, exon 21 mutations account for 35,9%. After treatment: complete response accounts for 5,2%. The rate of partial response patients was 48,6%, median progression-free survival time was 6,9 months, median overall survival time was 16,3 months.